This extension module explores the role of medicinal cannabis in palliative and end-of-life care. 
 
Learners will apply cannabinoid pharmacology to manage symptoms such as pain, nausea, appetite loss, and anxiety; differentiate between THC- and CBD-dominant products; and evaluate safety, efficacy, and impact of polypharmacy reduction.

With a focus on evidence-informed, patient-centred care, the module also addresses the legal, ethical, and practical considerations of initiating therapy in terminal care. 
 
A Case study will be presented to develop and assess clinical reasoning and practice management skills, identify knowledge gaps, and provide a framework for clinical supervision and feedback. 

Learning Outcomes

After completing this activity pharmacists should be able to:

1. Explain the increasing symptom burden and distress associated with end of life care.
2. Identify the potential therapeutic application of medicinal cannabinoids in relation to the symptoms of pain, nausea, appetite loss and anxiety in palliative care settings.
3. Differentiate between cannabinoid formulations and administration methods according to clinical need.

4. Consider the relative risks that medication interactions may pose in this popuulation.

5. Evaluate the safety, efficacy and polypharmacy-reduction potential of medicinal cannabis in end-of-life care.